Close X
Attorney Spotlight

Find out how Gardner Bell's experience promoting financial and economic development initiatives both locally and abroad informs his role as an attorney. Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

On December 1, 2016, Parker Hannifin Corporation and CLARCOR Inc. announced that the companies have entered into a definitive agreement under which Parker will acquire CLARCOR for approximately $4.3 billion in cash, including the assumption of net debt. The transaction has been unanimously approved by the board of directors of each company. Upon closing of the transaction, expected to be completed by or during the first quarter of Parker’s fiscal year 2018, CLARCOR will be combined with Parker’s Filtration Group to form a leading and diverse global filtration business. Bass, Berry & Sims has served CLARCOR as primary corporate and securities counsel for 10 years and served as lead counsel on this transaction. Read more here.

CLARCOR
Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Securities Law Exchange BlogSecurities Law Exchange blog offers insight on the latest legal and regulatory developments affecting publicly traded companies. It focuses on a wide variety of topics including regulation and reporting updates, public company advisory topics, IPO readiness and exchange updates including IPO announcements, M&A trends and deal news.

Read More >

Attorney Spotlight: Michael Hess

April 6, 2016

Mike Hess Spotlight1. What is an interesting trend happening right now related to the specialty pharmacy field?

Specialty pharmacy (SP) is experiencing explosive growth due to the rapid development of new biologics for the treatment of more and more chronic diseases. In fact, specialty drug spend is expected to increase from $55 billion (24% total drug spend) in 2005 to more than $400 billion by 2020 (approximately 50% of total drug spend). Three of the four costliest prescription therapy classes will be specialty conditions. This outsized growth continues to dwarf changes to most of other segments of the healthcare market and the U.S. economy as a whole. Further, even though SPs have been a separate market from pharmacy in general since the late 1990s, it continues to be an unstable and relatively immature market with new companies rapidly gaining scale and existing participants continuing to be very acquisitive.

2. You previously worked in-house as Chief Counsel. How does this background and perspective inform your interaction with firm clients? 

I learned so many important lessons that it is very hard to narrow. Most importantly, I learned that clients do not have "legal" problems, they just have problems, and they expect their lawyer to fix those problems. Solving a "legal" problem without considering the financial, personal or public relations aspects of the issue does not solve their problem – in fact it just leaves them without the solution they sought. Further, you always have to meet your client where they are. Presentation style, words and impressions matter. You may give the best advice, but if your client cannot hear you, it is worthless. Finally, never underestimate the importance of delivering the product your client wants. Listen to whether your client needs a quick answer or a lengthy treatise, then deliver what they need.

3. You've attended the Armada Specialty Pharmacy Summit for several years now. What do you always look forward to and enjoy about this event?

The Armada conference is the one time and place each year that the entire specialty pharmacy industry gathers. All of our clients attend, which gives us a great chance to spend an hour with their full teams in a casual, non-business focuses environment.


Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.